Oncogenic role of lncRNA SBF2-AS1 in bladder cancer.

Autor: Dos Anjos Oliveira E; Federal University of Ouro Preto, School of Pharmacy, Ouro Preto, Minas Gerais, Brazil., Cunha Almeida T; Butantan Institute, Laboratory of Pain and Signaling, Sao Paulo, São Paulo, Brazil., Nicioli da Silva G; Federal University of Ouro Preto, School of Pharmacy, Ouro Preto, Minas Gerais, Brazil; Butantan Institute, Laboratory of Pain and Signaling, Sao Paulo, São Paulo, Brazil. Electronic address: nicioli@ufop.edu.br.
Jazyk: angličtina
Zdroj: Gene [Gene] 2025 Jan 30; Vol. 935, pp. 149061. Date of Electronic Publication: 2024 Oct 30.
DOI: 10.1016/j.gene.2024.149061
Abstrakt: Introduction: Bladder cancer is a malignant neoplasm with increasing incidence rates. LncRNAs play an important role in cancer, including development, prognosis, and response to therapies. It is known that lncRNA SBF2-AS1 was associated with cell proliferation and worse prognosis in various tumor types, but its role remains incompletely understood in bladder cancer. In this context, our objective was to evaluate the effect of lncRNA SBF2-AS1 silencing on bladder cancer cells.
Methods: J82 and UM-UC-3 high-grade bladder tumor cells were treated with two siRNAs specific for SBF2-AS1 to evaluate cytotoxicity, clonogenic survival, morphology, cell migration, and cell cycle progression.
Results: Expression inhibition of SBF2-AS1 resulted in cytotoxicity, morphological changes, and decreased clone formation and cell migration. Cell cycle alterations were not observed.
Conclusion: Our study revealed that SBF2-AS1 plays an oncogenic role and holds promise as a potential target for the treatment of bladder cancer.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: